JJ Beats Earnings Estimates and Eyes Spinoff
Johnson and Johnson reported a higher quarterly profit driven by strong sales of Tremfya. The company raised its full-year forecasts and plans to spin off its orthopedics unit.
Xurve View
Insights:
Xurve View
JOHNSON & JOHNSON reported a third-quarter net profit that beat Wall Street estimates on Tuesday morning, powered by strong sales of its immune disease treatment Tremfya. The healthcare giant posted total revenue of $25.4 billion for the quarter, topping the $25.28 billion consensus estimate. The company also raised its full-year adjusted earnings guidance to a midpoint of $11.10 per share.
